1-7 of 7
Jessica R. Kirshner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P134: Novel EGFRvIII-selective antibody-drug conjugate REGN3124-PBD is strongly efficacious against orthotopic glioblastoma multiforme patient derived xenografts

Marcus P. Kelly, Sosina Makonnen, Carlos Hickey, Shu Mao, Feng Zhao, Arthur Kunz, Frank Delfino, Thomas Nittoli, Dangshe Ma, William C. Olson, Gavin Thurston, Jessica R. Kirshner
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P134.
https://doi.org/10.1158/1535-7163.TARG-21-P134
Published: 01 December 2021
View article titled, Abstract P134: Novel EGFRvIII-selective antibody-drug conjugate REGN3124-PBD is strongly efficacious against orthotopic glioblastoma multiforme patient derived xenografts
Journal Articles

Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers

Marcus P. Kelly, Carlos Hickey, Sosina Makonnen, Sandra Coetzee, Sumreen Jalal, Yu Wang, Frank Delfino, Jing Shan, Terra B. Potocky, Ishita Chatterjee, Julian Andreev, Arthur Kunz, Christopher D'Souza, Jason T. Giurleo, Thomas Nittoli, Pamela A. Trail, Gavin Thurston, Jessica R. Kirshner
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (7): 1299–1311.
https://doi.org/10.1158/1535-7163.MCT-16-0839
Published: 04 July 2017
View article titled, Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
Open the PDF for Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers in another window
Includes: Supplementary data
Journal Articles

Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs

Julian Andreev, Nithya Thambi, Andres E. Perez Bay, Frank Delfino, Joel Martin, Marcus P. Kelly, Jessica R. Kirshner, Ashique Rafique, Arthur Kunz, Thomas Nittoli, Douglas MacDonald, Christopher Daly, William Olson, Gavin Thurston
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (4): 681–693.
https://doi.org/10.1158/1535-7163.MCT-16-0658
Published: 02 April 2017
View article titled, Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Open the PDF for Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs in another window
Includes: Supplementary data
Journal Articles

Abstract A131: Rapid constitutive internalization and degradation of prolactin receptor (PRLR) is associated with potent cell killing by PRLR antibody drug conjugates (ADC)

Julian Andreev, NIthya Thambi, Frank Delfino, Joel Martin, Marcus P. Kelly, Jessica R. Kirshner, Douglas MacDonald, Nicholas Popadopoulos, Willian Olson, Gavin Thurston
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A131.
https://doi.org/10.1158/1535-7163.TARG-15-A131
Published: 01 December 2015
View article titled, Abstract A131: Rapid constitutive internalization and degradation of prolactin receptor (PRLR) is associated with potent cell killing by PRLR antibody drug conjugates (ADC)
Journal Articles

Abstract A193: Fully human bispecific antibodies induce potent anti-tumor effects against prostate tumors in mice

Alison Crawford, Kristin Vazzana, Jeffrey VanValkenburgh, Lauric Haber, Jennifer Principio, Cagan Gurer, Kara Olson, Eric Smith, Gavin Thurston, Jessica R. Kirshner
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A193.
https://doi.org/10.1158/1535-7163.TARG-15-A193
Published: 01 December 2015
View article titled, Abstract A193: Fully human bispecific antibodies induce potent anti-tumor effects against prostate tumors in mice
Journal Articles

Abstract C126: PRLR ADC: A novel antibody drug-conjugate for the treatment of PRLR positive breast cancer

Marcus P. Kelly, Sandra Coetzee, Carlos Hickey, Sosina Makonnen, Frank Delfino, Julian Andreev, Arthur Kunz, Christopher D'Souza, Jason Giurleo, Thomas Nittoli, Pamela A. Trail, Nicholas Papadopoulos, Gavin Thurston, Jessica R. Kirshner
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C126.
https://doi.org/10.1158/1535-7163.TARG-15-C126
Published: 01 December 2015
View article titled, Abstract C126: PRLR ADC: A novel antibody drug-conjugate for the treatment of PRLR positive breast cancer
Journal Articles

Elesclomol induces cancer cell apoptosis through oxidative stress

Jessica R. Kirshner, Suqin He, Vishwasenani Balasubramanyam, Jane Kepros, Chin-Yu Yang, Mei Zhang, Zhenjian Du, James Barsoum, John Bertin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (8): 2319–2327.
https://doi.org/10.1158/1535-7163.MCT-08-0298
Published: 21 August 2008
View article titled, Elesclomol induces cancer cell apoptosis through oxidative stress
Open the PDF for Elesclomol induces cancer cell apoptosis through oxidative stress in another window
Includes: Supplementary data